Posted by Michael Wonder on 30 Mar 2022
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm
30 March 2022 - Tagraxofusp is human interleukin-3 genetically conjugated to diphtheria toxin protein.
NICE is unable to make a recommendation on the use of tagraxofusp (Elzonris) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm because Stemline Therapeutics did not provide an evidence submission.
As usual, NICE will review this decision if Stemline Therapeutics decides to make a submission.
